Shire grabs $5B in funding to buy NPS; Alexion recalls more Soliris;

@FiercePharma: Check out our special issue devoted to ASCO14, with coverage from @JohnCFierce and @CarlyHFierce. More  | Follow @FiercePharma

@TracyStaton: ICYMI, @FiercePharma's report on the 10 best-selling cancer drugs of 2013. Preview: Roche still dominates the top. Report | Follow @TracyStaton

@EricPFierce: Teva has the 180 day exclusive for generic Celebrex in 3 popular doses and Mylan is unhappy about that. Story | Follow @EricPFierce

@CarlyHFierce: ASCO14: GSK misses survival endpoint with Tykerb-Herceptin pairing. News | Follow @CarlyHFierce

> Shire ($SHPG) has nabbed a $5 billion credit facility for a takeover offer for New Jersey's NPS Pharmaceuticals. Report

> Alexion ($ALXN) said it is voluntarily recalling certain lots of orphan drug Soliris. More

> The FDA has approved Omeros' ($OMER) Omidria for use in cataract and lens replacement surgeries. Report

> Canada's provinces have reached a tentative deal that will allow them to cover the cost of Vertex's ($VRTX) Kalydeco on their provincial drug plans. More

> India's Jubilant Pharma plans to raise more than $100 million to facilitate its corporate reorganization. Report

> Combining an older chemotherapy drug with standard hormone treatment early on helped men with advanced prostate cancer live more than a year longer, a study found. More

> Shasun Pharmaceuticals is betting big on formulations manufacturing and marketing in the regulated markets, eyeing a possible expansion in API capacity. More

Medical Device News

@FierceMedDev: Almac revealed that its new Dx spots ovarian cancer patients for whom Roche's Avastin would hurt. More from FierceDiagnostics | Follow @FierceMedDev

@VarunSaxena2: OIG to Review Medical Device Security. Story from GovInfoSecurity | Follow @VarunSaxena2

@MichaelGFierce: 'Nanodaisies' carry two cancer drugs and protect them in the bloodstream. More | Follow @MichaelGFierce

@EmilyWFierce: $AAPL poised to take a bite out of the health-monitoring market with a new tracking app. News via The New York Times | Follow @EmilyWFierce

> In Google Glass, doctors see a wearable medical device marvel, and some concerns. More

> Researchers use 3-D printing to create synthetic blood vessels. Story

> Chinese authorities slap J&J and rivals with $3M for price fixing. News

Biotech News

@FierceBiotech: ASCO14: Bristol-Myers immuno-oncology combo extends lives of patients in melanoma study. More | Follow @FierceBiotech

@JohnCFierce: Like a good David vs. Goliath story? Added Goliath -Clovis preps for a blockbuster showdown with AstraZeneca. Story | Follow @JohnCFierce

@DamianFierce: Latest on Shire and NPS: Times says it's moving forward. At what point does takeover comm. get involved? Article | Follow @DamianFierce

@EmilyMFierce: Sangamo's gene editing tech fixes immune flaw in stem cell study. More | Follow @EmilyMFierce

> Amgen pads its PCSK9 lead with latest data on a potential blockbuster. Story

> Bayer buys into PhIII-ready prostate cancer drug with $68M upfront. News

> CAR-Ts: Remissions now stretch toward 4 years. Twitter chat

CRO News

> Parexel picks a chief scientist to guide a transition. Item

> INC Research partners up to improve clinical trial sites. Report

> WuXi expands its Chinese ops as manufacturing brings in revenue. Article

> AMRI's paying $110M for a bolt-on CMO. Story

> Evotec buys a U.K. CRO with an eye on anti-infectives. News

Biotech IT News

> Roche makes $350M move for DNA sequencing business. Item

> Sequoia raises $530M to invest in Indian tech and health startups. Story

> Chinese upstart takes aim at Illumina with homegrown DNA sequencer. Article

> Investigator database looking for new members after adding Novartis and Pfizer to ranks. News

> Report: Pharma more vulnerable than other industries to hackers. More

And Finally... Apple ($AAPL) plans to introduce a new health-tracking app that will tally statistics like a user's footsteps, heart rate and sleep activity. Report (sub. req.)

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.